News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Isis Pharmaceuticals, Inc. Discusses its New ISIS 301012 Phase 2 Clinical Data Presented at the DALM Symposium
October 1, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
CARLSBAD, Calif., Oct. 1 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS - News) announces the following webcast:
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
MORE ON THIS TOPIC
CAR-T
Novartis pauses CAR T studies due to 3 deaths; BMS follows suit after safety events
September 1, 2026
·
3 min read
·
Tristan Manalac
Cardiovascular disease
Arrowhead’s new Redemplo findings in severe hypertriglyceridemia have analysts split
August 31, 2026
·
3 min read
·
Tristan Manalac
Cancer
BioNTech halts mid-stage trial of personalized mRNA vaccine in colorectal cancer
August 28, 2026
·
2 min read
·
Heather McKenzie
cardiovascular disease
‘Worse than expected’ Wainua data muddies water for TTR silencers
August 28, 2026
·
2 min read
·
Gabrielle Masson
